By Mill Chart
Last update: Sep 21, 2023
Our stock screener has singled out PFIZER INC (NYSE:PFE) as a promising choice for dividend investors. NYSE:PFE not only scores well in profitability, solvency, and liquidity but also offers a decent dividend. We'll explore this further.
ChartMill assigns a Dividend Rating to every stock. This score ranges from 0 to 10 and evaluates the different dividend aspects, including the yield, the growth and sustainability. NYSE:PFE scores a 8 out of 10:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NYSE:PFE, the assigned 5 for health provides valuable insights:
ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NYSE:PFE scores a 8 out of 10:
Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.
For an up to date full fundamental analysis you can check the fundamental report of PFE
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
NYSE:PFE (12/8/2023, 7:09:48 PM)Premarket: 28.9 +0.12 (+0.42%)
All three of these companies have seen brighter days.
Pfizer's stock recently hit a new 52-week low as the bad news continues for the pharma giant.
These are the blue-chip stocks to buy as they represent quality companies with a steady growth outlook and promising cash flow growth.
It's already planning to get back on the horse and make another attempt.
Pfizer (PFE) has received conditional approval for its immunotherapy elrexfio in the treatment of multiple myeloma.
Are you looking for the best tech stocks this holiday season? Here are seven stocks to light up your portfolio this holiday season.
If you’re holding F-rated stocks to sell, it may be too late to salvage 2023, but you can still get back on track toward achieving your goals.
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).
Private equity firm Bain Capital stands to make more than 10 times the $250 million it invested in Cerevel Therapeutics Holdings Inc following the neurology-focused drug developer's $8.7 billion sale to AbbVie Inc, according to regulatory filings. Boston-based Bain committed $350 million in 2018 to carve Cambridge, Massachusetts-based Cerevel out of Pfizer Inc, but only $250 million of that was drawn, the filings show. The deal with AbbVie, announced on Tuesday, now values Bain's 36.5% stake in Cerevel at about $2.7 billion.
Get an extensive Neuropsychiatric Disorders And Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.